HitGen Inc. is a Shanghai Stock Exchange listed drug discovery company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and in the US. HitGen has established has a powerful drug discovery platform encompassing DNA-Encoded Library (DEL) based small molecule drug discovery, Fragment- and Structure-Based Discovery, as well as targeted protein degradation. HitGen partners with many top 20 pharma and leading biotech companies to support their discovery organizations and pipelines. The company also has its own pipeline of pre-clinical and clinical assets in immunology and oncology for which it is searching for partners in Western markets.